Sandbox 645: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 41: | Line 41: | ||
1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'> tunnel tightly </scene>, which will prevent polyproteins from also binding. Saquniavir's chemical structure has the ability to <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'> mimic the tetrahedral </scene> intermediate of the hydrolytic reaction to interact <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> strongly with the catalytic Asp residues</scene> <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> </scene>. | 1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_tunnel/1'> tunnel tightly </scene>, which will prevent polyproteins from also binding. Saquniavir's chemical structure has the ability to <scene name='User:David_Canner/Sandbox_HIV/Hiv_morph2/9'> mimic the tetrahedral </scene> intermediate of the hydrolytic reaction to interact <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> strongly with the catalytic Asp residues</scene> <scene name='User:David_Canner/Sandbox_HIV/Saquinavir_cat/3'> </scene>. | ||
[[Image:Saquin1.gif| | [[Image:Saquin1.gif|1200px|thumb|center|Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.]] | ||
| Line 71: | Line 71: | ||
4) Nelfinavir (Viracept), Nelfinavir was approved by the FDA in March, 1997. <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[Viracept]]) has not been effectively evaluated in pregnant women. Viracept prevents T-cells that have been infected with HIV from producing new HIV. Usually given to patients through tablets. Each tablet contains inactive ingredients such as: calcium silicate, magnesium stearate, hypromellose, and triacetin.<ref>PMID:11364528</ref> | 4) Nelfinavir (Viracept), Nelfinavir was approved by the FDA in March, 1997. <scene name='User:David_Canner/Sandbox_HIV/Nelfinavir/2'>Nelfinavir</scene> ([[Viracept]]) has not been effectively evaluated in pregnant women. Viracept prevents T-cells that have been infected with HIV from producing new HIV. Usually given to patients through tablets. Each tablet contains inactive ingredients such as: calcium silicate, magnesium stearate, hypromellose, and triacetin.<ref>PMID:11364528</ref> | ||
[[Image:Nelfin1.gif| | [[Image:Nelfin1.gif|500px|thumb|center|Nelfinavir is slightly soluble in water at pH ≤ 4 and completely soluble in methanol.]] | ||
